High-density lipoprotein as a potential carrier for delivery of a lipophilic antitumoral drug into hepatoma cells.
OBJECTIVE
To investigate the possibility of recombinant high-density lipoprotein (rHDL) being a carrier for delivering antitumoral drug to hepatoma cells.


METHODS
Recombinant complex of HDL and aclacinomycin (rHDL-ACM) was prepared by cosonication of apoproteins from HDL (Apo HDL) and ACM as well as phosphatidylcholine. Characteristics of the rHDL-ACM were elucidated by electrophoretic mobility, including the size of particles, morphology and entrapment efficiency. Binding activity of rHDL-ACM to human hepatoma cells was determined by competition assay in the presence of excess native HDL. The cytotoxicity of rHDL-ACM was assessed by MTT method.


RESULTS
The density range of rHDL-ACM was 1.063-1.210 g/mL, and the same as that of native HDL. The purity of all rHDL-ACM preparations was more than 92%. Encapsulated efficiencies of rHDL-ACM were more than 90%. rHDL-ACM particles were typical sphere model of lipoproteins and heterogeneous in particle size. The average diameter was 31.26+/-5.62 nm by measure of 110 rHDL-ACM particles in the range of diameter of lipoproteins. rHDL-ACM could bind on SMMC-7721 cells, and such binding could be competed against in the presence of excess native HDL. rHDL-ACM had same binding capacity as native HDL. The cellular uptake of rHDL-ACM by SMMC-7721 hepatoma cells was significantly higher than that of free ACM at the concentration range of 0.5-10 microg/mL (P<0.01). Cytotoxicity of rHDL-ACM to SMMC-7721 cells was significantly higher than that of free ACM at concentration range of less than 5 microg/mL (P<0.01) and IC50 of rHDL-ACM was lower than IC50 of free ACM (1.68 nmol/L vs 3 nmol/L). Compared to L02 hepatocytes, a normal liver cell line, the cellular uptake of rHDL-ACM by SMMC-7721 cells was significantly higher (P<0.01) and in a dose-dependent manner at the concentration range of 0.5-10 microg/mL. Cytotoxicity of the rHDL-ACM to SMMC-7721 cells was significantly higher than that to L02 cells at concentration range of 1-7.5 microg/mL (P<0.01). IC50 for SMMC-7721 cells (1.68 nmol/L) was lower than that for L02 cells (5.68 nmol/L), showing a preferential cytotoxicity of rHDL-ACM for SMMC-7721 cells.


CONCLUSIONS
rHDL-ACM complex keeps the basic physical and biological binding properties of native HDL and shows a preferential cytotoxicity for SMMC-7721 hepatoma to normal L02 hepatocytes. HDL is a potential carrier for delivering lipophilic antitumoral drug to hepatoma cells.
Lou
Bin
B
Department of Biochemistry, School of Pharmacy, Fudan University, Shanghai 200032, China.
Liao
Xue-Ling
XL
Wu
Man-Ping
MP
Cheng
Pei-Fang
PF
Yin
Chun-Yan
CY
Fei
Zheng
Z
D015250:Aclarubicin / Q000031:analogs & derivatives* / Q000493:pharmacokinetics*; D000903:Antibiotics, Antineoplastic / Q000493:pharmacokinetics*; D006528:Carcinoma, Hepatocellular; D045744:Cell Line, Tumor; D004337:Drug Carriers / Q000493:pharmacokinetics*; D022781:Hepatocytes / Q000166:cytology / Q000187:drug effects; D006801:Humans; D008075:Lipoproteins, HDL / Q000493:pharmacokinetics*; D008113:Liver Neoplasms
D000903:Antibiotics, Antineoplastic; D004337:Drug Carriers; D008075:Lipoproteins, HDL; C011157:aclacinomycins; D015250:Aclarubicin
Biopharm Drug Dispos. 1995 Mar;16(2):91-103
7780050
Eur J Med Chem. 2000 Apr;35(4):429-38
10858603
J Lipid Res. 1984 Jun;25(6):550-8
6747459
Atherosclerosis. 2003 Jan;166(1):31-40
12482548
Biochim Biophys Acta. 2000 May 31;1485(2-3):129-44
10832094
J Lipid Res. 1966 Mar;7(2):295-306
4957797
Methods Enzymol. 1986;128:155-70
3724500
Adv Drug Deliv Rev. 2001 Apr 25;47(2-3):251-76
11311995
Biochemistry. 1994 Nov 29;33(47):14073-80
7947817
Biochim Biophys Acta. 1994 Jan 11;1225(2):125-34
8280780
Crit Rev Ther Drug Carrier Syst. 1990;7(2):99-120
2272100
J Immunother Emphasis Tumor Immunol. 1994 Jan;15(1):42-52
8110730
Biochim Biophys Acta. 1979 May 25;573(2):375-81
221035
Science. 1996 Jan 26;271(5248):518-20
8560269
Mol Med Today. 1999 Dec;5(12):518-24
10562717
Br J Cancer. 1993 Aug;68(2):319-26
8347487
Anticancer Res. 1997 Mar-Apr;17(2A):1143-6
9137462
J Biol Chem. 1987 Feb 25;262(6):2435-42
3029080
J Control Release. 1998 Nov 13;55(2-3):231-43
9795069
J Control Release. 2002 Apr 23;80(1-3):29-44
11943385
Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai). 1996;28(6):659-664
12232594
J Drug Target. 2000;8(3):155-64
10938525
Bioconjug Chem. 1994 Mar-Apr;5(2):105-13
8031872
Br J Cancer. 1989 Oct;60(4):523-8
2529890
Radiat Res. 1999 Sep;152(3):250-6
10453085
Cancer Chemother Pharmacol. 1992;29(3):241-7
1733558
Nature. 2003 Jan 2;421(6918):75-9
12511957
Annu Rev Biochem. 1977;46:897-930
197883
Biochim Biophys Acta. 1986 Jun 11;877(1):135-40
3718995
Ann N Y Acad Sci. 1987;507:252-71
3442366
Cancer Chemother Pharmacol. 1992;29(5):396-400
1551179
Support Care Cancer. 1996 Jul;4(4):298-304
8829309